Continuous

Novel Integration of Process Analytical Technologies for Continuous Biomanufacturing

Edita Botonjic-Sehic, Ph.D.

ReciBioPharm

Radioconjugates

Rising Interest in Radioconjugate Therapies

Cynthia A. Challener, Ph.D.

Pharma's Almanac

CDMO

The Improvements of the Production and Stability of a mAb-Chelator Conjugate by Modified Transchelation Conditions

Hyung-il Lee, Ph.D.

GBI

Radioconjugate development

Expediting Radioimmune Conjugate Pharmaceuticals for First-In-Human Phase 0 Proof-of-Concept Human Studies from Stable Pool

Muctarr Sesay, Ph.D.; Natalia Bourguignon, Ph.D.

GBI

Antibody-Drug Conjugates

Reducing ADC Development Timelines with Integrated Development and Manufacturing Services

Thomas Rohrer

Samsung Biologics

Biomanufacturing

New Name, Same Expertise: Goodwin Biotechnology is Becoming GBI!

Danielle Alvarez

Pharma's Almanac

Opioid Conjugate Vaccines

Vaccines Present a Novel Strategy for Opioid Overdose Prevention

Muctarr Sesay, Ph.D.

GBI

Speed to Clinic

Leveraging Experience to Reduce Timelines for IND-Enabling Activities

Muctarr Sesay, Ph.D.; Andrew Majdoch, M.Sc.

GBI

Theranostics

Theranostic Manufacturing Solutions

Muctarr Sesay, Ph.D.

GBI

ADCS

Improving the Therapeutic Index of ADCs with a Peptide Linker Technology

Philipp Spycher

Araris Biotech AG

Antibody-Drug Conjugates

Accelerating ADC Development with Advanced Payload Intermediates

David Goeddel, Ph.D.

MilliporeSigma

Antibody–Drug Conjugates

Preparing for the ADC Explosion with End-to-End Support

Jyothi Swamy, Ph.D.; Elizabeth McKee

MilliporeSigma

Antibody–Drug Conjugates

Linking Novel Medicines to Patients with Hard-to-Treat Cancers for Improved Quality of Life

Loretta Itri, M.D., F.A.C.P.,; Usama Malik

Immunomedics

In Conversation

Novel Off-The-Shelf Targeted Cell Therapies

David Alvaro, Ph.D.; Sonny Hsiao, Ph.D.

Pharma's Almanac

Antibody-Drug Conjugate

Fast-Tracking ADC Development and Commercialization

Matteo Piazza

PROVEO

Antibody-Drug Conjugate

Increasing the Potency of Antibody–Drug Conjugates

Philipp Spycher

Araris Biotech AG

FDA Approval

Genetech’s Antibody–Drug Conjugate Receives FDA Approval

Pharma's Almanac

ADC

Integrating ADC Manufacturing for the Future

Mark Frigerio, Ph.D.; Juan Carlos Cordova, Ph.D.

Abzena

ADC

Speeding up ADC Development With the Right Partner Organization

Courtney Morgret, Ph.D.

AbbVie Contract Manufacturing

Antibody-Drug Conjugates

Rapid Growth in the ADC Market Drives Strategic Partnership Interest

Allan Davidson

Piramal Pharma Solutions